JOHANNESBURG (AP) – South Africa’s efforts to produce vaccines are key to helping the African continent become more self-sufficient in inoculations to combat COVID-19 and many other diseases, the visiting World Health Organization (WHO) chief said recently.
On his visit to Cape Town, WHO Director-General Tedros Ghebreyesus is viewing three facilities starting work to manufacture vaccines.
Tedros visited the Biomedical Research Institute at the Tygerberg campus of Stellenbosch University on Friday. He is also scheduled to visit Afrigen Biologics and Vaccines and the Biovac laboratories in Cape Town.
The pandemic had shown the need for local production of vaccines in low and middle-income countries, he said addressing a press briefing.
“Over half of the world’s population is now fully vaccinated, and yet 84 per cent of the population of Africa is yet to receive a single dose,” he said. “Much of this inequity has been driven by the fact that globally vaccine production is concentrated in a few, mostly high-income countries. One of the most obvious lessons of the pandemic, therefore, is the urgent need to increase local production of vaccines, especially in low and middle-income countries.”
Tedros was also scheduled to visit the Afrigen lab that, with support from the WHO, is creating a COVID-19 vaccine from scratch. The laboratory is replicating the Moderna vaccine using mRNA vaccine technology. The Afrigen facility has backing from WHO and several other partners including the governments of South Africa, France and Belgium. The initiative is also supported by the Africa Centers for Disease Control and Prevention.
Tedros said it is expected that clinical trials for the vaccine candidate developed by Afrigen would start in 2022 and it is hoped that approval for its use will be granted in 2024.
